A Phase Ib Study of Indirect Immunization with Oregovomab and Toll-like-Receptor-3 Stimulation with Hiltonol® in Patients with Recurrent Platinum-Resistant Ovarian Cancer
Current Oncology · 2025
DOI: 10.3390/curroncol32100532 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Current Oncology, 2025. Verfasst von Robert W Holloway und 6 weiteren Autor:innen. Beteiligte Einrichtung: Gynecologic Oncology Program, AdventHealth Cancer Institute, Orlando, FL 32804, USA. Hauptthemen laut MEDLINE: Neoplasm Recurrence, Local, Ovarian Neoplasms, Poly I-C, Polylysine. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: OncoQuest Pharmaceuticals, Inc. Edmonton, AB, Canada., OncoQuest Pharmaceuticals, Inc., Edmonton, AB, Canada.
Abstract (Originalsprache)
Objectives
This phase Ib study assessed the safety and compatibility of indirect oregovomab immunization and Toll-like-receptor-3 (TLR3) stimulation with immune adjuvant Hiltonol® (poly-ICLC) and induced clinically relevant CA125-specific anti-tumor immunity in heavily pretreated patients with progressive platinum-resistant ovarian cancer (PROC).
Methods
Patients with elevated serum CA125 level >50 U/mL received four intravenous infusions with 2 mg oregovomab followed by 2 mg Hiltonol® intramuscular 30 min and 48 h post-oregovomab at weeks 0, 3, 6, and 9. At week 12, imaging was performed, and salvage chemotherapy was allowed post-progression per the investigator’s discretion. The Fifth/final oregovomab with Hiltonol® infusion was given at week 16.
Results
Fifteen enrolled patients were analyzed for safety and efficacy. Thirteen (87%) patients completed at least three Hiltonol® infusions with oregovomab, specifically, two cycles (n = 2), three cycles (n = 2), four cycles (n = 3), and five cycles (n = 8). Adverse events included mild fatigue, flu-like symptoms, chills, axillary pain, and injection site discomfort in 13 (87%) patients. Serious adverse events were reported in seven (47%) patients, including Grade 3 hypertension (n = 2), thrombocytopenia (n = 1), and Grade 3 events attributed to underlying disease (n = 4). Ten (67%) patients had disease progression, three (20%) had stable disease, and two were unevaluable. Early humoral response by week 6 was observed in seven of nine (77%) patients, median progression-free survival was 2.7 months (95% confidence interval [CI]: 2.2, 3.3), and median overall survival was 15.0 months (95% CI: 8.2–23.9).
Conclusions
The safety and compatibility of combining oregovomab with Hiltonol® have been demonstrated in this study. The potential to enhance activity of chemotherapy using oregovomab indirect immunization and Hiltonol® stimulation is proposed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gynecologic Oncology Program, AdventHealth Cancer Institute, Orlando, FL 32804, USA.
- Division of Gynecologic Oncology, Virginia Commonwealth University, Richmond, VA 23298, USA.
- CanariaBio, Inc., Seoul 06044, Gyeonggi-do, Republic of Korea.
ORCID-Profile: Robert W Holloway, Sarah M Temkin, Sarah W Gordon, Sarfraz Ahmad
Förderung
- OncoQuest Pharmaceuticals, Inc. Edmonton, AB, Canada.
- OncoQuest Pharmaceuticals, Inc., Edmonton, AB, Canada
Zitieren
APA
Holloway, R. W., Temkin, S. M., Gordon, S. W., Gupta, S., Jada, S. R., Ahmad, S., & McGuire, W. P. (2025). A Phase Ib Study of Indirect Immunization with Oregovomab and Toll-like-Receptor-3 Stimulation with Hiltonol® in Patients with Recurrent Platinum-Resistant Ovarian Cancer. Current Oncology. https://doi.org/10.3390/curroncol32100532
Vancouver
Holloway RW, Temkin SM, Gordon SW, Gupta S, Jada SR, Ahmad S, et al. A Phase Ib Study of Indirect Immunization with Oregovomab and Toll-like-Receptor-3 Stimulation with Hiltonol® in Patients with Recurrent Platinum-Resistant Ovarian Cancer. Current Oncology. 2025. doi:10.3390/curroncol32100532
BibTeX
@article{Holloway2025,
author = {Holloway, Robert W and Temkin, Sarah M and Gordon, Sarah W and Gupta, Sunil and Jada, Srinivasa R and Ahmad, Sarfraz and McGuire, William P},
title = {A Phase Ib Study of Indirect Immunization with Oregovomab and Toll-like-Receptor-3 Stimulation with Hiltonol® in Patients with Recurrent Platinum-Resistant Ovarian Cancer},
journal = {Current Oncology},
year = {2025},
doi = {10.3390/curroncol32100532}
}
EUVIMED